<DOC>
	<DOC>NCT01192139</DOC>
	<brief_summary>The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/500 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana [IN]) to coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, IN) in fed healthy subjects.</brief_summary>
	<brief_title>Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)</brief_title>
	<detailed_description>This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/500 mg metformin extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, Indiana)</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive Ages 18 to 45, inclusive Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population Major surgical procedure within 4 weeks prior to randomization Positive serology test for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease History of gastrointestinal disease within the past 3 months Any clinically significant medical condition that could potentially affect your participation in the study and/or personal wellbeing, as judged by the investigator Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization Unable to tolerate oral and/or intravenous (IV) medications Unable to tolerate the puncturing of veins for drawing of blood Known allergy or hypersensitivity to any component of the study medication History of any significant drug allergies (such as anaphylaxis or hepatotoxicity) Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>